Karbamazepina: interakcje

CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during YONSA treatment. (etykieta leku Abirateron, Interakcje z innymi lekami)

• Moderate to Strong Inhibitors of Both CYP2C19 and CYP2C9, or Strong or Moderate CYP2C19 or CYP2C9 Inducers : Avoid concomitant use. (etykieta leku Abrocytynib, Interakcje z innymi lekami)

• CYP3A Inducers: Avoid co-administration with strong CYP3A inducers. (etykieta leku Akalabrutynib, Interakcje z innymi lekami)

Łączenie alkoholu z lekami o działaniu uspokajającym (opioidami, benzodiazepinami, lekami nasennymi, lekami zwiotczającymi mięśnie) może powodować niebezpieczną senność, spowolnienie oddychania i przedawkowanie. (NIAAA, Harmful Interactions: Mixing Alcohol with Medicines)

CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (etykieta leku Alpelisyb, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (etykieta leku Karbamazepina, Przeciwwskazania)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (etykieta leku Karbamazepina, Przeciwwskazania)

• Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (etykieta leku Apiksaban, Interakcje z innymi lekami)

Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur ( 5.5 , 7.1 ) (etykieta leku Apremilast, Ostrzeżenia i środki ostrożności)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Antiepileptics: carbamazepine ↓ atazanavir ↑ carbamazepine Coadministration of REYATAZ (with or without ritonavir) with carbamazepine is contraindicated due to the risk for loss of virologic response and development of resistance [see Contraindications (4) ]. phenytoin, phenobarbital ↓ atazanavir ↓ phenytoin ↓ phenobarbital Coadministration of REYATAZ (with or… (etykieta leku Atazanawir, Interakcje z innymi lekami)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with azelastine hydrochloride and fluticasone propionate nasal spray because further decreased alertness and impairment of CNS performance may occur. (etykieta leku Azelastyna + flutykazon, Ostrzeżenia i środki ostrożności)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Concomitant administration of BIXLENVO is contraindicated with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events. strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO. (etykieta leku Biktegrawir + emtrycytabina + alafenamid tenofowiru, Przeciwwskazania)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (etykieta leku Karbamazepina, Przeciwwskazania)

Strong CYP3A4 Inducers: Avoid concomitant use. (etykieta leku Bortezomib, Interakcje z innymi lekami)

• Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (etykieta leku Bosutynib, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Avoid concurrent use of QUZYTTIR with alcohol or other CNS depressants because additional reduction in alertness and additional impairment of CNS performance may occur. (etykieta leku Cetyryzyna, Ostrzeżenia i środki ostrożności)

If concomitant administration with carbamazepine or phenobarbital cannot be avoided, frequent monitoring of anticonvulsant drug concentrations is recommended. (etykieta leku Chinina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [see Contraindications ( 4.2 )]. (etykieta leku Cyprofloksacyna, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance… (etykieta leku Darunawir, Przeciwwskazania)

Co-administration of PREZCOBIX or PREZCOBIX PED with CYP3A inducers may lead to lower exposures of darunavir and cobicistat and potential loss of efficacy of darunavir and possible resistance. (etykieta leku Darunawir + kobicystat, Przeciwwskazania)

If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (etykieta leku Dazatynib, Interakcje z innymi lekami)

Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy ( 7.1 ) (etykieta leku Deflazakort, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CONTRAINDICATIONS Diphenoxylate hydrochloride and atropine sulfate is contraindicated in: • Pediatric patients less than 6 years of age due to the risks of respiratory and central nervous system (CNS) depression (see WARNINGS ). (etykieta leku Difenoksylat + atropina, Przeciwwskazania)

Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (etykieta leku Diwalproeks (walproinian), Ostrzeżenie w ramce)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (etykieta leku Karbamazepina, Przeciwwskazania)

• Avoid concomitant use of doxorubicin hydrochloride with inhibitors and inducers of CYP3A4, CYP2D6, and/or P-gp ( 7.1 ) (etykieta leku Doksorubicyna, Interakcje z innymi lekami)

PIFELTRO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of PIFELTRO [see Warnings and Precautions (5.2) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ] . (etykieta leku Dorawiryna, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Rifampin and Other CYP3A Inducers Avoid rifampin or other CYP3A inducers such as phenobarbital, carbamazepine, phenytoin, and St. (etykieta leku Dronedaron, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Therefore, concomitant use with strong CYP3A inducers is not recommended [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (etykieta leku Eleksakaftor + tezakaftor + iwakaftor, Ostrzeżenia i środki ostrożności)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Alpha 1-adrenoreceptor antagonist: alfuzosin Anticonvulsants: carbamazepine, phenobarbital, phenytoin Antimycobacterial: rifampin Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine Herbal Products: St. (etykieta leku Elwitegrawir + kobicystat + emtrycytabina + tenofowir, Przeciwwskazania)

…virologic response and possible resistance to COMPLERA or to the class of NNRTIs [see Warnings and Precautions (5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose)… (etykieta leku Emtrycytabina + rylpiwiryna + tenofowir, Przeciwwskazania)

Avoid smoking tobacco (CYP1A2 inducer) and avoid concomitant use of erlotinib with moderate CYP1A2 inducers (e.g., teriflunomide, rifampin, or phenytoin). (etykieta leku Erlotynib, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Serious and sometimes fatal dermatologic reactions, including TEN and SJS, have also been reported in patients using oxcarbazepine or carbamazepine which are chemically related to APTIOM. (etykieta leku Eslikarbazepina, Ostrzeżenia i środki ostrożności)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Etravirine should not be used in combination with carbamazepine, phenobarbital, or phenytoin as co-administration may cause significant decreases in etravirine plasma concentrations and loss of therapeutic effect of Etravirine. (etykieta leku Etrawiryna, Interakcje z innymi lekami)

IT IS NOT KNOWN WHETHER CONCOMITANT USE OF OTHER ANTIEPILEPTIC DRUGS AND/OR OTHER DRUGS AFFECT THE INCIDENCE OF HEPATIC FAILURE. (etykieta leku Felbamat, Ostrzeżenie w ramce)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Consider avoiding phenytoin as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.5) ] . (etykieta leku Fenytoina, Ostrzeżenia i środki ostrożności)

Preventing or Managing DI The concomitant use of ADDYI with CYP3A4 inducers is not recommended. (etykieta leku Flibanseryna, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

…Hypericum perforatum ) Lipid modifying agents: Lomitapide, lovastatin, simvastatin Non-nucleoside reverse transcriptase inhibitor: Delavirdine PDE5 inhibitor: Sildenafil (Revatio) (for treatment of pulmonary arterial hypertension) Sedative/hypnotics: Midazolam, triazolam Hypersensitivity to fosamprenavir calcium or amprenavir (e.g., Stevens-Johnson syndrome). (etykieta leku Fosamprenawir, Przeciwwskazania)

Intervention Avoid concomitant use of FOCINVEZ Examples rifampin, carbamazepine, phenytoin (etykieta leku Fosaprepitant, Interakcje z innymi lekami)

Consider avoiding CEREBYX as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers. (etykieta leku Fosfenytoina, Ostrzeżenia i środki ostrożności)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. (etykieta leku Hydroksyzyna, Środki ostrożności)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (etykieta leku Karbamazepina, Przeciwwskazania)

• Strong CYP3A4 Inducers: Do not administer strong CYP3A4 inducers with CAMPTOSAR. (etykieta leku Irynotekan, Interakcje z innymi lekami)

Carbamazepine Not recommended 2 weeks before, during, and 2 weeks after TOLSURA treatment. (etykieta leku Itrakonazol, Interakcje z innymi lekami)

Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etykieta leku Iwabradyna, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (etykieta leku Karbamazepina, Przeciwwskazania)

• Coadministration with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, and rifapentine. (etykieta leku Kabotegrawir, Przeciwwskazania)

Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. (etykieta leku Kabozantynib, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Avoid concurrent use of Carbinoxamine Maleate Extended-Release Oral Suspension with alcohol or other central nervous system depressants because additional impairment of central nervous system performance may occur. (etykieta leku Karbinoksamina, Ostrzeżenia i środki ostrożności)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. (etykieta leku Ketokonazol, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Avoid use with other central nervous system (CNS) depressants ( 5.3 ) (etykieta leku Klonidyna, Ostrzeżenia i środki ostrożności)

As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ] . (etykieta leku Klopidogrel, Ostrzeżenia i środki ostrożności)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. (etykieta leku Kwas walproinowy, Ostrzeżenie w ramce)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Lapatinib The use of carbamazepine with lapatinib should generally be avoided. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4 inducers with VITRAKVI. (etykieta leku Larotrektynib, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Concomitant administration of SUNLENCA with carbamazepine or phenytoin is contraindicated. (etykieta leku Lenakapawir, Interakcje z innymi lekami)

Avoid concurrent use of alcohol or other central nervous system depressants with XYZAL. (etykieta leku Lewocetyryzyna, Ostrzeżenia i środki ostrożności)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

KALETRA once daily in combination with carbamazepine, phenobarbital, or phenytoin is not recommended. (etykieta leku Lopinawir + rytonawir, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Effect of Other Drugs on LORBRENA Strong CYP3A Inducers LORBRENA is contraindicated in patients taking strong CYP3A inducers [see Contraindication (4) ] . (etykieta leku Lorlatynib, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ). (etykieta leku Macytentan, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Avoid co-administration of mifepristone and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, and St. (etykieta leku Mifepryston, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (etykieta leku Naldemedyna, Interakcje z innymi lekami)

Risk of Recurrent Respiratory and CNS Depression : A recurrence of respiratory depression is possible, therefore, keep the patient under continued surveillance and administer repeat doses of ZURNAI using a new auto-injector with each dose while awaiting emergency medical assistance. (etykieta leku Nalmefen, Ostrzeżenia i środki ostrożności)

Strong CYP3A4 inducers (e.g., rifampin) : Decreased concentrations of naloxegol; concomitant use is not recommended. (etykieta leku Naloksegol, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Concomitant use of nefazodone. (etykieta leku Karbamazepina, Przeciwwskazania)

John’s Wort reduce the bioavailability and efficacy of nifedipine; therefore nifedipine should not be used in combination with strong CYP3A inducers such as rifampin (See CONTRAINDICATIONS ). (etykieta leku Nifedypina, Interakcje z innymi lekami)

Strong CYP3A Inducers: Avoid concomitant use with CAVHANZA. (etykieta leku Nilotynib, Interakcje z innymi lekami)

…contraindicated with drugs that are primarily metabolized by CYP3A and for which elevated concentrations are associated with serious and/or life-threatening reactions and drugs that are strong CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance. (etykieta leku Nirmatrelwir + rytonawir, Przeciwwskazania)

Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) -- - ---------- ------ USE IN SPECIFIC POPULATIONS---- -- -- --------- ---- Lactation: Not recommended; Lo Loestrin Fe can decrease milk production ( 8.2 ) (etykieta leku Noretysteron + etynyloestradiol, Interakcje z innymi lekami)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions ( 5.2 )]. (etykieta leku Oksybat sodu, Ostrzeżenie w ramce)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

• Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal solution (nasal spray) ( 5.2 ). (etykieta leku Olopatadyna, Ostrzeżenia i środki ostrożności)

• Avoid concurrent use of alcohol or other central nervous system (CNS) depressants with RYALTRIS because additional reductions in alertness and additional impairment of CNS performance may occur. (etykieta leku Olopatadyna + mometazon, Ostrzeżenia i środki ostrożności)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Avoid concomitant use of strong CYP3A inducers (e.g., phenytoin, rifampin, carbamazepine, enzalutamide, and St John's Wort) [see Clinical Pharmacology (12.3) ] . (etykieta leku Palbocyklib, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (etykieta leku Pazopanib, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see Clinical Pharmacology (12.3) ] . (etykieta leku Pirfenidon, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

• Patients taking strong Cytochrome P450 3A enzyme (CYP3A) inducers, such as rifampin, [see Warnings and Precautions ( 5.6 ) and Drug Interactions ( 7.1 , 7.2 )] . (etykieta leku Prazykwantel, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

ASPRUZYO Sprinkle is contraindicated in patients: Taking strong inhibitors of CYP3A [see Drug Interactions (7.1)] Taking inducers of CYP3A [see Drug Interactions (7.1)] With liver cirrhosis [see Use in Specific Populations (8.6)] Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nelfinavir) (4, 7.1) (etykieta leku Ranolazyna, Przeciwwskazania)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Therefore the use of strong cytochrome P450 inducers (e.g., rifampicin, phenobarbital, carbamazepine, and phenytoin) with DALIRESP is not recommended [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3) ]. (etykieta leku Roflumilast, Interakcje z innymi lekami)

Intervention: Avoid the use of VARUBI in patients who require chronic administration of strong CYP3A4 inducers. (etykieta leku Rolapitant, Interakcje z innymi lekami)

• Avoid use with rifampin and strong CYP3A4 inducers ( 7.3 ). (etykieta leku Romidepsyna, Interakcje z innymi lekami)

Table 2: Drugs That are Contraindicated with EDURANT and EDURANT PED Drug Class Contraindicated Drugs in Class Clinical Comment Anticonvulsants Carbamazepine Oxcarbazepine Phenobarbital Phenytoin Potential for significant decreases in rilpivirine plasma concentrations due to CYP3A enzyme induction, which may result in loss of virologic response. (etykieta leku Rylpiwiryna, Przeciwwskazania)

• Strong and Moderate CYP3A Inducers: Avoid concomitant administration. (etykieta leku Rymegepant, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

• Certain CYP3A inducers: Coadministration with strong inducers of CYP3A is not recommended. (etykieta leku Rytlecytynib, Interakcje z innymi lekami)

WARNING: DRUG-DRUG INTERACTIONS LEADING TO POTENTIALLY SERIOUS AND/OR LIFE THREATENING REACTIONS Co-administration of NORVIR with several classes of drugs including sedative hypnotics, antiarrhythmics, or ergot alkaloid preparations may result in potentially serious and/or life-threatening adverse events due to possible effects of NORVIR on the hepatic metabolism… (etykieta leku Rytonawir, Ostrzeżenie w ramce)

Drugs that Induce Cytochrome P450 3A Enzymes and Drug Transport Systems Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin, St. (etykieta leku Rywaroksaban, Interakcje z innymi lekami)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (etykieta leku Karbamazepina, Przeciwwskazania)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Anticonvulsants: carbamazepine phenytoin phenobarbital ↓ sofosbuvir ↓ velpatasvir ↓ voxilaprevir Coadministration is not recommended. (etykieta leku Sofosbuwir + welpataswir, Interakcje z innymi lekami)

• Strong CYP3A Inducers: Avoid strong CYP3A4 inducers. (etykieta leku Sorafenib, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Interaction with Strong Inhibitors and Inducers of CYP3A4 and/or P-gp Avoid concomitant use of sirolimus with strong inhibitors of CYP3A4 and/or P-gp (such as ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampin or rifabutin) [ see Drug Interactions (7.2) ]. (etykieta leku Syrolimus, Ostrzeżenia i środki ostrożności)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (etykieta leku Tamoksyfen, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Temsirolimus The use of concomitant strong CYP3A4 inducers such as carbamazepine should be avoided with temsirolimus. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

• Avoid use with strong CYP3A inhibitors or CYP3A inducers. (etykieta leku Tikagrelor, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Avoid co-administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and strong CYP3A4 inducers (e.g., rifampin, phenytoin) with TEPADINA due to the potential effects on efficacy and toxicity [see Clinical Pharmacology ( 12.3 ) ] . (etykieta leku Tiotepa, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Avoid concomitant use of SAMSCA with strong CYP3A inducers. (etykieta leku Tolwaptan, Interakcje z innymi lekami)

Coadministration with a strong CYP3A4 inducer may result in a relevant decrease in FARESTON exposure and should be avoided. (etykieta leku Toremifen, Interakcje z innymi lekami)

CYP3A inducers: Avoid concomitant strong CYP3A inducers ( 7.1 ) (etykieta leku Trabektedyna, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Concomitant use of monoamine oxidase inhibitors (MAOIs). (etykieta leku Karbamazepina, Przeciwwskazania)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Avoid concomitant use with strong CYP3A inducers if possible. (etykieta leku Tretynoina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Known hypersensitivity to any of the tricyclic compounds (e.g., amitriptyline, desipramine, imipramine, protriptyline, and nortriptyline.) Hypersensitivity reactions include anaphylaxis and serious rash. (etykieta leku Karbamazepina, Przeciwwskazania)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Strong CYP3A4 Inducers: Should be avoided as concomitant use will result in reduction of ubrogepant exposure. (etykieta leku Ubrogepant, Interakcje z innymi lekami)

Avoid co-administration of ella and drugs or herbal products such as: • barbiturates • bosentan • carbamazepine • felbamate • griseofulvin • oxcarbazepine • phenytoin • rifampin • St. (etykieta leku Uliprystal, Interakcje z innymi lekami)

Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. (etykieta leku Upadacytynib, Interakcje z innymi lekami)

Strong CYP3A Inducers : Avoid concomitant use with strong CYP3A inducers. (etykieta leku Vepdegestrant, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Known hypersensitivity to tricyclic antidepressants ( 4 ) (etykieta leku Karbamazepina, Przeciwwskazania)

Carbamazepine (CYP450 Induction) Not Studied In Vivo or In Vitro , but Likely to Result in Significant Reduction Contraindicated Long Acting Barbiturates (e.g., phenobarbital, mephobarbital) (CYP450 Induction) Not Studied In Vivo or In Vitro , but Likely to Result in Significant Reduction Contraindicated Phenytoin (CYP450 Induction) Significantly Reduced Increase… (etykieta leku Worykonazol, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS Depressants The concomitant use of EQUETRO and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

CYP3A4/5 Inducers Co-administration of rifampin, a strong inducer of CYP3A4/5, reduced the plasma exposure of axitinib in healthy volunteers. (etykieta leku Aksytynib, Interakcje z innymi lekami)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (etykieta leku Albendazol, Ostrzeżenia i środki ostrożności)

Inform patients also that the central nervous system depressant effects of allopurinol tablets may be additive to those of alcohol and other CNS depressants. (etykieta leku Allopurynol, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

…infants <3 months of age Sepsis with multi-organ failure Shock Cessation of Smoking Drug Interactions Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin) (see PRECAUTIONS , Drug Interactions , Table II ). (etykieta leku Aminofilina, Ostrzeżenia)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etykieta leku Amlodypina, Interakcje z innymi lekami)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etykieta leku Amlodypina + atorwastatyna, Interakcje z innymi lekami)

Blood pressure should be monitored when amlodipine is coadministered with CYP3A4 inducers (e.g. rifampicin, St. (etykieta leku Amlodypina + benazepryl, Interakcje z innymi lekami)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (etykieta leku Amlodypina + olmesartan, Interakcje z innymi lekami)

Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e.g. rifampicin, St. (etykieta leku Amlodypina + walsartan, Interakcje z innymi lekami)

CYP1A2 inducers: CYP1A2 inducers could decrease the exposure of AGRYLIN. (etykieta leku Anagrelid, Interakcje z innymi lekami)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Warfarin (CYP1A2 and CYP3A4 Substrate) Through induction of CYP1A2 and CYP3A4, EQUETRO decreases the concentration of warfarin and decreases its anticoagulant effectiveness. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase Inhibitors, Nonselective Beta-Adrenergic… (etykieta leku Artykaina + adrenalina, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Beklometazon, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with Bendamustine Hydrochloride Injection. (etykieta leku Bendamustyna, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Clinically Significant Interactions with Bexagliflozin Tablets UGT Enzyme Inducers Clinical Impact UGT Enzyme Inducers may significantly reduce exposure to bexagliflozin and lead to a decreased efficacy [ see Clinical Pharmacology ( 12.3 )]. (etykieta leku Bexagliflozin, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Warfarin (CYP1A2 and CYP3A4 Substrate) Through induction of CYP1A2 and CYP3A4, EQUETRO decreases the concentration of warfarin and decreases its anticoagulant effectiveness. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Therefore, potent inhibitors or inducers of CYP3A4 may increase or reduce the circulating levels of CYCLOSET, respectively. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Use with CNS depressants may result in an additive or potentiating effect. (etykieta leku Brymonidyna, Interakcje z innymi lekami)

Use with CNS depressants may result in an additive or potentiating effect. (etykieta leku Brymonidyna + tymolol, Interakcje z innymi lekami)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, post menopausal status, tobacco use, advance age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Budezonid, Ostrzeżenia i środki ostrożności)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Budezonid + formoterol, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Bupiwakaina, Ostrzeżenia i środki ostrożności)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Bupiwakaina + adrenalina, Ostrzeżenia i środki ostrożności)

Triazolam/flurazepam: Coadministration of buspirone with either triazolam or flurazepam did not appear to prolong or intensify the sedative effects of either benzodiazepine. (etykieta leku Buspiron, Interakcje z innymi lekami)

Drug monitoring may be of assistance in detecting alterations in carbamazepine plasma concentrations. (etykieta leku Cefiksym, Interakcje z innymi lekami)

Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g., fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of celecoxib. (etykieta leku Celekoksyb, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (etykieta leku Chloroprokaina, Środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Antibiotics † Local anesthetics Magnesium salts Procainamide Lithium Quinidine May prolong the neuromuscular blockade action of Cisatracurium Besylate Injection Phenytoin, Carbamazepine May increase resistance to the neuromuscular blockade action of Cisatracurium Besylate Injection resulting in shorter durations of neuromuscular blockade and infusion rate requirements… (etykieta leku Cisatrakurium, Interakcje z innymi lekami)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Cyklezonid, Ostrzeżenia i środki ostrożności)

The rate of metabolism and the leukopenic activity of cyclophosphamide are reportedly increased by chronic co-administration of CYP3A4 inducers. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Warfarin (CYP1A2 and CYP3A4 Substrate) Through induction of CYP1A2 and CYP3A4, EQUETRO decreases the concentration of warfarin and decreases its anticoagulant effectiveness. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Therapy with danazol may cause an increase in carbamazepine levels in patients taking both drugs. (etykieta leku Danazol, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Clinically Relevant Interactions Affecting DEXILANT When Coadministered with Other Drugs and Substances CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of dexlansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (etykieta leku Dekslanzoprazol, Interakcje z innymi lekami)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (etykieta leku Desmopresyna, Interakcje z innymi lekami)

Alcohol or other sedating drugs: May have additive sedation and somnolence ( 7.5 ) (etykieta leku Deutetrabenazyna, Interakcje z innymi lekami)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Exercise caution when prescribing ZIPSOR with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, antiepileptics). (etykieta leku Diklofenak, Ostrzeżenia i środki ostrożności)

Exercise caution when prescribing diclofenac sodium/misoprostol with concomitant drugs that are known to be potentially hepatotoxic (e.g., antibiotics, anti-epileptics). (etykieta leku Diklofenak + mizoprostol, Ostrzeżenia i środki ostrożności)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (etykieta leku Dofetylid, Interakcje z innymi lekami)

Examples Glutethimide and phenobarbital Intervention If a patient initiates or discontinues therapy with an enzyme inducer, dose adjustment of doxercalciferol may be necessary. (etykieta leku Dokserkalcyferol, Interakcje z innymi lekami)

Barbiturates, carbamazepine and phenytoin decrease the half-life of doxycycline. (etykieta leku Doksycyklina, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Carbamazepine a ↓Dolutegravir Adjust dose of TIVICAY to twice daily in treatment-naïve or treatment-experienced, INSTI-naïve adult patients. (etykieta leku Dolutegrawir, Interakcje z innymi lekami)

Following the administration of droperidol, the dose of other CNS depressant drugs should be reduced. (etykieta leku Droperydol, Interakcje z innymi lekami)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Warfarin (CYP1A2 and CYP3A4 Substrate) Through induction of CYP1A2 and CYP3A4, EQUETRO decreases the concentration of warfarin and decreases its anticoagulant effectiveness. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Strong CYP 3A4 inducers: Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. (etykieta leku Eksemestan, Interakcje z innymi lekami)

Other Agents Anticonvulsants: carbamazepine oxcarbazepine phenobarbital phenytoin ↓ TAF Consider alternative anticonvulsant. (etykieta leku Emtrycytabina + tenofowir, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Warfarin (CYP1A2 and CYP3A4 Substrate) Through induction of CYP1A2 and CYP3A4, EQUETRO decreases the concentration of warfarin and decreases its anticoagulant effectiveness. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of INVANZ re-examined to determine whether it should be decreased or discontinued. (etykieta leku Ertapenem, Ostrzeżenia i środki ostrożności)

Drugs that Inhibit Epoxide H ydrolase and CYP3A4 Clarithromycin, erythromycin, loxapine, quetiapine, and valproate also inhibit epoxide hydrolase, resulting in increased levels of the active metabolite carbamazepine-10,11-epoxide [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Karbamazepina, Interakcje z innymi lekami)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Table 4: Clinically Relevant Interactions Affecting Esomeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of esomeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ]. (etykieta leku Ezomeprazol, Interakcje z innymi lekami)

Anticonvulsants - In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (e.g., phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers. (etykieta leku Felodypina, Interakcje z innymi lekami)

Phenobarbital Clinical Impact: Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen. (etykieta leku Fenoprofen, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. (etykieta leku Flekainid, Interakcje z innymi lekami)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids), should be monitored and treated with established standards of care. (etykieta leku Flutykazon, Ostrzeżenia i środki ostrożności)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Flutykazon + salmeterol, Ostrzeżenia i środki ostrożności)

Reciprocal interactions may occur with concomitant use of fomepizole and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied. (etykieta leku Fomepizol, Interakcje z innymi lekami)

Warfarin (CYP1A2 and CYP3A4 Substrate) Through induction of CYP1A2 and CYP3A4, EQUETRO decreases the concentration of warfarin and decreases its anticoagulant effectiveness. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

• CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (etykieta leku Gefitynib, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

…and its plasma concentrations can be significantly affected resulting in an increase in exposure Consider dose reduction [see Dosage and administration (2.7) ] Strong and moderate CYP3A4 inducers, e.g., rifampin, efavirenz Guanfacine is primarily metabolized by CYP3A4 and its plasma concentrations can be significantly affected resulting in a decrease in exposure… (etykieta leku Guanfacyna, Interakcje z innymi lekami)

Warfarin (CYP1A2 and CYP3A4 Substrate) Through induction of CYP1A2 and CYP3A4, EQUETRO decreases the concentration of warfarin and decreases its anticoagulant effectiveness. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Concomitant administration of inducers of CYP3A4 may lead to decreases in serum concentrations of ALKINDI SPRINKLE and increase the risk of adverse reactions, including adrenal crisis. (etykieta leku Hydrokortyzon, Interakcje z innymi lekami)

• CYP3A4 Inducers: Monitor for increased toxicity when used in combination with CYP3A4 inducers. (etykieta leku Ifosfamid, Interakcje z innymi lekami)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of PRIMAXIN re-examined to determine whether it should be decreased, or the antibacterial drug discontinued ( 5.2 ). (etykieta leku Imipenem + cylastatyna, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Table 7: Clinically Significant Drug Interactions with INVOKANA UGT Enzyme Inducers Clinical Impact: UGT enzyme inducers decrease canagliflozin exposure which may reduce the effectiveness of INVOKANA. (etykieta leku Kanagliflozyna, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

…When Caspofungin acetate for Injection is co-administered to adult patients with other inducers of hepatic CYP enzymes, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, administration of a daily dose of 70 mg of Caspofungin acetate for Injection should be considered [see Dosage and Administration ( 2.5 ) and Clinical Pharmacology ( 12.3… (etykieta leku Kaspofungina, Interakcje z innymi lekami)

Drugs that Inhibit Epoxide H ydrolase and CYP3A4 Clarithromycin, erythromycin, loxapine, quetiapine, and valproate also inhibit epoxide hydrolase, resulting in increased levels of the active metabolite carbamazepine-10,11-epoxide [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Inducers of CYP3A4 and CYP3A5 Inducers of CYP3A4 and/or CYP3A5 may reduce plasma concentrations of clindamycin. (etykieta leku Klindamycyna, Interakcje z innymi lekami)

Anticonvulsants Salicylic acid can displace protein-bound phenytoin and valproic acid, leading to a decrease in the total concentration of phenytoin and an increase in serum valproic acid levels. (etykieta leku Kwas acetylosalicylowy + dipirydamol, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Effects of VYKOURA on Other Drugs Certain Antiepileptic Drugs Increase monitoring for seizure activity in patients taking certain concomitant antiepileptic drugs. (etykieta leku Kwas folinowy (leukoworyna), Interakcje z innymi lekami)

Te leki przeciwpadaczkowe obniżają stężenie folianów, a suplementy kwasu foliowego mogą z kolei obniżać stężenie leku we krwi. (NIH Office of Dietary Supplements, Folate)

Effects of Leucovorin Products on Other Drugs Antiepileptic Drugs Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and primidone and increase the frequency of seizures in susceptible children. (etykieta leku Kwas lewofolinowy, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Clinically Relevant Interactions Affecting PREVACID or PREVACID SoluTab When Coadministered with Other Drugs CYP2C19 OR CYP3A4 Inducers Clinical Impact: Decreased exposure of lansoprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ] . (etykieta leku Lanzoprazol, Interakcje z innymi lekami)

Anticonvulsants: carbamazepine phenytoin phenobarbital ↓ ledipasvir ↓ sofosbuvir Coadministration of ledipasvir and sofosbuvir with carbamazepine, phenytoin, or phenobarbital is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of ledipasvir and sofosbuvir. (etykieta leku Ledipaswir + sofosbuwir, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. (etykieta leku Lewotyroksyna, Interakcje z innymi lekami)

Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. (etykieta leku Lidokaina + adrenalina, Ostrzeżenia i środki ostrożności)

…prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sufonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (etykieta leku Lidokaina + prylokaina, Interakcje z innymi lekami)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (etykieta leku Linagliptyna, Interakcje z innymi lekami)

Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. (etykieta leku Linagliptyna + metformina, Interakcje z innymi lekami)

Phenytoin and carbamazepine reduce serum protein binding of thyroid hormones, and total and FT4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. (etykieta leku Liotyronina, Interakcje z innymi lekami)

Lithium Concomitant administration of EQUETRO and lithium can increase the risk of neurotoxic adverse reactions. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Risk of CNS Depression with Concomitant use of CNS Depressant Drugs : Lofexidine tablets potentiates the CNS depressant effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates, and other sedating drugs. (etykieta leku Lofeksydyna, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

• If patients with severe renal impairment or ESRD receiving SELZENTRY (without concomitant CYP3A inducers or inhibitors) experience postural hypotension, the dose of SELZENTRY should be reduced from 300 mg twice daily to 150 mg twice daily. (etykieta leku Marawirok, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Anticonvulsants In patients taking an anticonvulsant (e.g., valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant. (etykieta leku Meflochina, Interakcje z innymi lekami)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Inducers of CYP3A4 (e.g., phenytoin, carbamazepine, dexamethasone, rifampin, and phenobarbital) could increase the rate of elimination of donepezil. (etykieta leku Memantyna + donepezyl, Interakcje z innymi lekami)

…procaine, ropivacaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine (etykieta leku Mepiwakaina, Interakcje z innymi lekami)

Additive Effects Since the effects of meprobamate and alcohol or meprobamate and other CNS depressants or psychotropic drugs may be additive,appropriate caution should be exercised with patients who take more than one of these agents simultaneously. (etykieta leku Meprobamat, Ostrzeżenia)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

CYP3A4 inducers Drugs (e.g. nevirapine, rifampin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate. (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin) : Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etykieta leku Metyloprednizolon, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Concurrent use of metyrosine with alcohol or other CNS depressants can increase their sedative effects. (etykieta leku Metyrozyna, Interakcje z innymi lekami)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants and corticosteroids) should be monitored and treated with established standards of care. (etykieta leku Mometazon, Ostrzeżenia i środki ostrożności)

WARNINGS AND PRECAUTIONS Risk of Recurrent Respiratory and CNS Depression : Due to the duration of action of naloxone relative to the opioid, respiratory and CNS depression may recur after the first dose of naloxone. (etykieta leku Nalokson, Ostrzeżenia i środki ostrożności)

Table 4: Clinically Significant Interactions with Esomeprazole Magnesium - Affecting Co-Administered Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact : Decreased exposure of esomeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (12.3) ]. (etykieta leku Naproksen + ezomeprazol, Interakcje z innymi lekami)

Anticonvulsants: Carbamazepine, clonazepam, ethosuximide Plasma concentrations of nevirapine and the anticonvulsant may be decreased. (etykieta leku Newirapina, Interakcje z innymi lekami)

Possible Reduced Efficacy with Strong CYP3A4 Inducers Concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. (etykieta leku Nimodypina, Ostrzeżenia i środki ostrożności)

Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. (etykieta leku Nintedanib, Interakcje z innymi lekami)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Omeprazol, Interakcje z innymi lekami)

Table 6: Clinically Relevant Interactions Affecting Omeprazole when Co-Administered with Other Drugs CYP2C19 or CYP3A4 Inducers Clinical Impact: Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Omeprazol + wodorowęglan sodu, Interakcje z innymi lekami)

Phenytoin, Carbamazepine, and Rifampin In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. (etykieta leku Ondansetron, Interakcje z innymi lekami)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (etykieta leku Orlistat, Ostrzeżenia i środki ostrożności)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Strong CYP3A4 Inducers: Decreased exposure of WAKIX; consider dosage adjustment of WAKIX ( 2.6 , 7.1 ) (etykieta leku Pitolisant, Interakcje z innymi lekami)

Strong CYP3A4 and UGT1A1 Inducers In vitro assessments and limited clinical data indicated that concomitant use of strong CYP3A4 and UGT1A1 inducers (e.g., rifampin, phenytoin, carbamazepine) may decrease the systemic exposure of ponesimod. (etykieta leku Ponesimod, Interakcje z innymi lekami)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CYP 3A4 inducers (e.g. barbiturates, phenytoin, carbamazepine, and rifampin): Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of prednisolone and require that the dosage of Orapred be increased. (etykieta leku Prednizolon, Interakcje z innymi lekami)

CYP 3A4 inducers and inhibitors: May, respectively, increase or decrease clearance of corticosteroids, necessitating dose adjustment. (etykieta leku Prednizon, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

EQUETRO can reduce the effectiveness of hormonal contraceptives. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

CYP1A2 and CYP2C19 Inducers: CYP1A2 inducers (e.g., phenytoin, montelukast, smoking) and CYP2C19 inducers (e.g. rifampin) decrease the plasma levels of propranolol resulting in a loss of efficacy [see Clinical Pharmacology ( 12.7 )] . (etykieta leku Propranolol, Interakcje z innymi lekami)

…cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine The administration of local anesthetic injections containing… (etykieta leku Prylokaina + adrenalina, Interakcje z innymi lekami)

CYP2C8 and CYP3A4 Inducers Intervention: Repaglinide tablets dose increases and increased frequency of glucose monitoring may be required when co‑administered. (etykieta leku Repaglinid, Interakcje z innymi lekami)

Reduced Rocuronium Bromide Injection activity possible : Anticonvulsants. (etykieta leku Rokuronium, Interakcje z innymi lekami)

• Inhibitors or inducers of CYP1A2: May alter the clearance of ropinirole; dose adjustment of ropinirole may be required. (etykieta leku Ropinirol, Interakcje z innymi lekami)

…cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants Phenobarbital, phenytoin, sodium valproate Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine NAROPIN should be used with caution in patients receiving… (etykieta leku Ropiwakaina, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (etykieta leku Ruksolitynib, Interakcje z innymi lekami)

Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. (etykieta leku Ryfabutyna, Interakcje z innymi lekami)

…Hormonal Contraceptives Prevention or Management: Advise patients to change to non-hormonal methods of birth control during rifampin therapy Estrogens Decrease exposure Progestins Anticonvulsants Phenytoin Administered with rifampin 450 mg daily Decrease exposure Antiarrhythmics Disopyramide Decrease exposure Mexiletine Decrease exposure Quinidine Decrease exposure… (etykieta leku Ryfampicyna, Interakcje z innymi lekami)

…Disopyramide, mexiletine, quinidine, tocainide Antibiotics Chloramphenicol, clarithromycin, dapsone, doxycycline; Fluoroquinolones (such as ciprofloxacin) Oral Anticoagulants Warfarin Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam… (etykieta leku Ryfapentyna, Interakcje z innymi lekami)

Strong to moderate CYP1A2 inducers: Co-administration may result in decreased efficacy ( 7.2 ) (etykieta leku Ryluzol, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

• CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etykieta leku Sunitynib, Interakcje z innymi lekami)

CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) increase CIALIS exposure ( 2.7 , 5.10 , 7.2 ) requiring dose adjustment: CIALIS for use as needed: no more than 10 mg every 72 hours CIALIS for once daily use: dose not to exceed 2.5 mg CYP3A4 inducers (e.g. rifampin) decrease CIALIS exposure ( 7.2 ). (etykieta leku Tadalafil, Interakcje z innymi lekami)

Tacrolimus When carbamazepine is used with tacrolimus, monitoring of tacrolimus blood concentrations and appropriate dosage adjustments are recommended. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Patients should be monitored for adequate clinical effect when amlodipine is co-administered with CYP3A4 inducers. (etykieta leku Telmisartan + amlodypina, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Cessation of Smoking: Drug Interactions: Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin). (etykieta leku Teofilina, Ostrzeżenia)

Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor. (etykieta leku Terbinafina, Interakcje z innymi lekami)

Alcohol or Other Sedating Drugs Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence [see Warnings and Precautions (5.7) ] . (etykieta leku Tetrabenazyna, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

…exposure to tofacitinib Intervention Dosage modification of XELJANZ/XELJANZ XR is recommended [see Dosage and Administration (2) , Clinical Pharmacology, Figure 3 (12.3) ] Strong CYP3A4 Inducers (e.g., rifampin) Clinical Impact Decreased exposure to tofacitinib and may result in loss of or reduced clinical response Intervention Concomitant use with XELJANZ/XELJANZ… (etykieta leku Tofacytynib, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. (etykieta leku Treprostynil, Ostrzeżenia i środki ostrożności)

Hepatic enzyme inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin): Drugs which induce hepatic microsomal drug metabolizing enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. (etykieta leku Triamcynolon, Interakcje z innymi lekami)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

The recent use of other drugs that cause CNS depression or EPS symptoms may also increase the risk; consider reducing the dosage or discontinuing the drug. (etykieta leku Trimetobenzamid, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Phenytoin, fosphenytoin: Adjustment of anticonvulsant and/or tinidazole dose(s) may be needed ( 7.1, 7.2 ) (etykieta leku Tynidazol, Interakcje z innymi lekami)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Warfarin (CYP1A2 and CYP3A4 Substrate) Through induction of CYP1A2 and CYP3A4, EQUETRO decreases the concentration of warfarin and decreases its anticoagulant effectiveness. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

It may be necessary to reduce the EQUETRO dose if used concomitantly with inhibitors of CYP3A4 and/or epoxide hydrolase. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

Drug Interactions The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. (etykieta leku Winkrystyna, Interakcje z innymi lekami)

Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN, including phenytoin. (etykieta leku Karbamazepina, Ostrzeżenia i środki ostrożności)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. (etykieta leku Afatynib, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

N e uromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Anticonvulsant therapy can be given if clinically indicated. (etykieta leku Cefaleksyna, Ostrzeżenia i środki ostrożności)

Anticonvulsant therapy should be continued in patients with known seizure disorders. (etykieta leku Cefazolina, Ostrzeżenia i środki ostrożności)

Cytochrome (CYP) 3A4 inhibitors, epoxide hydrolase inhibitors, CYP3A4 inducers, drugs metabolized by CYP1A2 or CYP3A4 (oral contraceptives, delavirdine, nefazodone), phenytoin, CNS depressants, lithium, chloroquine, mefloquine ( 7.1 , 7.2 , 7.3 ) (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (etykieta leku Deksamfetamina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

• Cytochrome P450 3A4 inducers, inhibitors, or substrates: May alter docetaxel metabolism. (etykieta leku Docetaksel, Interakcje z innymi lekami)

In Drug-Induced CNS and Respiratory Depression Doxapram alone may not stimulate adequate spontaneous breathing or provide sufficient arousal in patients who are severely depressed either due to respiratory failure or to CNS depressant drugs, but may be used as an adjunct to established supportive measures and resuscitative techniques. (etykieta leku Doksapram, Ostrzeżenia)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

The following drugs are CYP3A4 inhibitors: Acetazolamide, aprepitant, azole antifungals (e.g., ketoconazole, itraconazole, fluconazole, voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

The “gasping syndrome” is characterized by central nervous system (CNS) depression, metabolic acidosis, and gasping respirations. (etykieta leku Epoetyna alfa, Ostrzeżenia i środki ostrożności)

Such drugs include the following: Aminophylline, c isplatin, doxorubicin, felbamate, phosphenytoin, methsuximide , phenobarbital, phenytoin, primidone, rifampin and theophylline. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Effects of Other Drugs on HALAVEN No drug-drug interactions are expected with CYP3A4 inhibitors, CYP3A4 inducers or P-glycoprotein (P-gp) inhibitors. (etykieta leku Erybulina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Such drugs include the following: Aminophylline, c isplatin, doxorubicin, felbamate, phosphenytoin, methsuximide , phenobarbital, phenytoin, primidone, rifampin and theophylline. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Potential for Glycerol Phenylbutyrate to Affect Other Drugs Drugs with narrow therapeutic index that are substrates of CYP3A4 Glycerol phenylbutyrate is a weak inducer of CYP3A4 in humans. (etykieta leku Fenylomaślan glicerolu, Interakcje z innymi lekami)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…itraconazole, fluconazole, voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, quinine, quinupristin, ticlopidine, troleandomycin, valproate,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Antiepileptics The activity of antiepileptic drugs might be impaired if co-administered with PLAQUENIL. (etykieta leku Hydroksychlorochina, Interakcje z innymi lekami)

…fluconazole, voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, quinine, quinupristin, ticlopidine, troleandomycin, valproate, verapamil,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…fluconazole, voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, quinine, quinupristin, ticlopidine, troleandomycin, valproate, verapamil,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

N e uromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…alprazolam, aprepitant, buprenorphone, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Antiepileptic Drugs Sporadic cases of seizures have been reported during concomitant use of ketorolac tromethamine and antiepileptic drugs (phenytoin, carbamazepine). (etykieta leku Ketorolak, Interakcje z innymi lekami)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

The following drugs are CYP3A4 inhibitors: Acetazolamide, aprepitant, azole antifungals (e.g., ketoconazole, itraconazole, fluconazole, voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Effect on CYP1A2 Substrates Teriflunomide, the active metabolite of ARAVA, may be a weak inducer of CYP1A2 in vivo . (etykieta leku Leflunomid, Interakcje z innymi lekami)

…dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phenytoin,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, quinine, quinupristin, ticlopidine, troleandomycin, valproate, verapamil, zileuton. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexiletine, lowered mexiletine plasma levels have been reported. (etykieta leku Meksyletyna, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Anticonvulsants, psychotropic, hormone preparations, corticosteroids, antithyroid agents, cyproheptadine: may affect the results of the metyrapone test. (etykieta leku Metyrapon, Interakcje z innymi lekami)

The following drugs are CYP3A4 inhibitors: Acetazolamide, aprepitant, azole antifungals (e.g., ketoconazole, itraconazole, fluconazole, voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…alprazolam, aprepitant, buprenorphone, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…alprazolam, aprepitant, buprenorphone, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

N e uromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Drugs metabolized by CYP3A4 or CYP1A2 include the following: Acetaminophen, albendazole, alprazolam, aprepitant, buprenorphone, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…fluconazole, voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, quinine, quinupristin, ticlopidine, troleandomycin, valproate, verapamil,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Such drugs include the following: Aminophylline, c isplatin, doxorubicin, felbamate, phosphenytoin, methsuximide , phenobarbital, phenytoin, primidone, rifampin and theophylline. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS however),… (etykieta leku Prazosyna, Interakcje z innymi lekami)

…dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phenytoin,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Moreover, in vitro , raltegravir did not induce CYP1A2, CYP2B6 or CYP3A4. (etykieta leku Raltegrawir, Interakcje z innymi lekami)

Strong CYP3A inducers: Strong inducers of CYP3A (for example, rifampin, phenytoin, carbamazepine, phenobarbital or St. (etykieta leku Riocyguat, Interakcje z innymi lekami)

CYP3A4 Substrates An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Ryfaksymina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

N e uromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

Effect of AUBAGIO on CYP1A2 Substrates Teriflunomide may be a weak inducer of CYP1A2 in vivo . (etykieta leku Teryflunomid, Interakcje z innymi lekami)

…dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phenytoin,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

These data suggest that GH may alter the clearance of compounds known to be metabolized by CYP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, and cyclosporine). (etykieta leku Tesamorelina, Interakcje z innymi lekami)

…dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phenytoin,… (etykieta leku Karbamazepina, Interakcje z innymi lekami)

N e uromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

N e uromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

No formal drug-drug interaction studies with zafirlukast and other drugs known to be metabolized by the cytochrome P450 2C9 isoenzyme (e.g., tolbutamide, phenytoin, carbamazepine) have been conducted; however, care should be exercised when zafirlukast is coadministered with these drugs . (etykieta leku Zafirlukast, Środki ostrożności)

…voriconazole ) , cimetidine, ciprofloxacin, clarithromycin, dalfopristin, danazol, dantrolene, delavirdine, diltiazem, erythromycin, fluoxetine, fluvoxamine, grapefruit juice, ibuprofen, isoniazid, loratadine, nefazodone, niacinamide, nicotinamide, olanzapine, omeprazole, oxybutynin, quinine, quinupristin, ticlopidine, troleandomycin, valproate, verapamil, zileuton. (etykieta leku Karbamazepina, Interakcje z innymi lekami)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3) ]. (etykieta leku Montelukast, Interakcje z innymi lekami)

CYP2C19 and CYP3A4 Inducer Co-administration of Micafungin in Sodium Chloride Injection with rifampin and ritonavir did not alter the pharmacokinetics of micafungin. (etykieta leku Mykafungina, Interakcje z innymi lekami)